The inaccessibility of human heart tissue is a barrier for the pathogenesis study of genetic heart diseases, the emergence of patient-derived induced pluripotent stem cells (iPSCs) and genome editing tools such as CRISPR/Cas9 strategy may provide an exciting new approach to understand disease mechanisms underpinning inherited heart diseases.[18,19] In the future, we will further evaluate the pathogenicity of LAMA4 c.652G > A (p.G218R) mutation using CRISPR/Cas9 gene editing method to create mutant mice or using patient-specific iPSCs -derived cardiomyocytes. This evidence concerns the gene LAMA4 and heart disorder.